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The physiological adaptations resulting in the development of the metabolic syndrome 
in man occur over a time span of several decades. This combined with the prohibitive 
financial cost and ethical concerns to measure key metabolic parameters repeatedly in 
subjects for the major part of their life span, makes that comprehensive longitudinal 
human data sets are virtually non-existent. While experimental mice are often used, 
little is known whether this species is in fact an adequate model to better understand 
the mechanisms that drive the metabolic syndrome in man. 
We took up the challenge to study the response of male apoE*3-Leiden.CETP mice 
(with a humanized lipid profile) to a high-fat high-cholesterol diet for six months. 
Study parameters include body weight, food intake, plasma and liver lipids, hepatic 
transcriptome, VLDL – triglyceride production and importantly the use of stable 
isotopes to measure hepatic de novo lipogenesis, gluconeogenesis, and biliary/fecal 
sterol secretion to assess metabolic fluxes. 
The key observations include 1) high inter-individual variation, 2) a largely unaffected 
hepatic transcriptome at 2, 3 and 6 months, 3) a biphasic response curve of the main 
metabolic features over time, and 4) maximum insulin resistance preceding 
dyslipidemia. The biphasic response in plasma triglyceride and total cholesterol 
appears to mimic that of men in cross-sectional studies. Combined, these observations 
suggest that studies such as these can help to delineate the causes of metabolic 
derangements in patients suffering from metabolic syndrome. 
 
Abbreviations 
HFCD, high-fat high-cholesterol diet; TG, triglyceride; TC, total cholesterol; VLDL, 
very low-density lipoprotein; LDL, low-density lipoprotein; HDL, high-density 
lipoprotein; CETP, cholesteryl ester transfer protein 
 
Introduction 
The physiologic adaptations resulting in the development of the metabolic syndrome in 
man occur over a time span of several decades. For example, central adiposity builds 
up over a time-frame of years and decades [1,2]. Furthermore, studies suggest that 
parameters of metabolic syndrome such as insulin resistance, muscle mass, plasma 
triglycerides and low-density lipoprotein cholesterol (LDL-c) are age-dependent [3,4]. 
Moreover, the relation between these parameters and age appears non-linear. A cross-
sectional study in Japan showed biphasic responses for body mass index, serum 
triglycerides and LDL-c in men, but not for women [3]. Finally, a cross-sectional study 
performed in a predominantly Caucasian cohort showed nonlinear relationship between 
age and skeletal muscle mass [4]. It is not clear why these age-associated changes 
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occur, but decreased physical activity and a decrease in growth-hormone and gonadal 
hormones have been proposed as possible explanations [3,4]. In contrast, insulin 
resistance appears to only increase with increasing age [5]. In any case, time is an 
important factor, and a longitudinal setup should therefore be preferred above a cross-
sectional setup to elucidate the mechanisms orchestrating metabolic syndrome.  
Although scarce, some longitudinal studies of metabolic syndrome in man have been 
performed. Scuteri et al. found that triglycerides in men increased with time, however 
decreased in healthy men in the 65 – 75 year age group, while in women triglycerides 
increased in all age groups [6]. Furthermore, Meigs et al. found that increased fasting 
glucose does not necessarily progress to diabetes when subjects are followed for over 
10 years [7]. Hamer et al. found that 45% of subjects classified as being “healthy 
obese” progressed to an unhealthy state (e.g. high triglycerides, impaired glycemic 
control) compared to 16% of normal-weight subjects over a period of 8-years [8]. 
While these longitudinal studies are very valuable, a major limitation is that (more 
laborious) metabolic flux measurements (i.e. VLDL – triglyceride (TG) production, 
sterol balance) have not been carried out, and for obvious reasons such studies can only 
sample a fraction of the human lifespan.  
Animal models of metabolic syndrome allow for studying metabolic alterations during 
development of metabolic syndrome in a shorter time-frame [9]. However, translation 
is limited by species-specific characteristics and responses to perturbations designed to 
induce metabolic syndrome [10]. For example, the fact that mice have very efficient 
clearance of triglyceride-rich lipoproteins, limits extrapolation to humans, who 
generally achieve higher plasma TG concentrations [11]. Similarly, while mice carry 
most of their plasma cholesterol in high-density lipoprotein (HDL), humans have a 
large LDL-c fraction [12]. To mitigate these species-specific differences, we make use 
of ‘humanized’ apoE*3-Leiden.CETP (E3L.CETP) mice, in which the apoE*3-Leiden 
transgene confers reduced clearance of triglyceride-rich lipoprotein (i.e. chylomicron- 
and VLDL-remnants), and the cholesteryl ester transfer protein (CETP) transgene 
further adds to a cholesterol profile more closely resembling that of humans [13]. 
Interestingly, in contrast to other mouse models of atherosclerosis, the E3L.CETP 
mouse has been shown to respond similar to treatment with statins, fibrates and 
ezetimibe as humans in terms of changes in plasma cholesterol and atherosclerotic 
progression [14]. Moreover, E3L.CETP respond similar to humans to antidiabetic 
drugs as well [15]. However, whether E3L.CETP mice are a good model to study the 
development of metabolic syndrome through time is unclear to date.  
Here, we study whether male E3L.CETP mice are an adequate model to study 
metabolic syndrome in man, by following their response to a high-fat high-cholesterol 
diet (HFCD) for six months. We found that both dyslipidemia and parameters of 
insulin resistance followed a biphasic trajectory. A biphasic trajectory in dyslipidemia 
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is also found in man during ageing. These data indicate that male E3L.CETP mice on 





Animals, diet and housing 
Male E3L.CETP mice [12,16] were housed individually and fed a synthetic HFCD diet 
containing 60% fat in energy and 0.25% cholesterol in weight (D12429, Research 
Diets) in a light (lights on 7:00 AM - lights off 7:00 PM) and temperature-controlled 
(21 °C) facility. Prior to the start of the experimental period, mice were co-housed with 
siblings and fed chow ad libitum with unlimited access to drinking water. At least one 
week prior to the start of the experiment animals were housed individually to 
acclimatize. Experimental procedures were approved by the Ethics Committees for 
Animal Experiments of the University of Groningen.  
 
Experimental setup 
Mice were fed a HFCD diet at the age of 4 months. Four cohorts of mice were fed 
HFCD diet ad libitum for 4 (n=20), 9 (n=19), 13 (n=20) and 28 weeks (n=30) 
respectively. At the end of the dietary intervention, mice in the respective cohorts were 
distributed evenly in two groups, where one group underwent measuring of VLDL-TG 
production and the other group was used for measuring hepatic de novo lipogenesis, 
for bile cannulation and for tissue collection. Animals were distributed over the two 
groups in the week of termination by placing every consecutive age-sorted mouse in a 
different group. An additional cohort (n=16) was used specifically for measuring 
endogenous glucose production at week 3, 9, 15 and 27 of the dietary intervention. 
These animals also underwent either VLDL–TG production measurement or bile-
cannulation and tissue collection. In all groups, blood samples were obtained by tail 
bleeding at 4 to 6 week intervals, to determine plasma TG, plasma total cholesterol 
(TC), HDL-c and glucose. In addition, 24-hr feces was collected from all groups at 4 to 
6 week intervals. All flux measurements and blood sample collections were started at 1 
PM in the fasting condition, with food removed at 9 AM.  
 
Drop outs 
Of 115 animals included in the study in total 10 animals (2 in the 13 weeks cohort, and 
8 in the respective 28 weeks cohorts) had to be terminated prematurely because of 
rapid weight loss, which in seven cases coincided with excessive grooming, scratching 
and scratch marks. No cause was found for the other three cases. Data of these animals 
obtained prior to termination were not excluded for analysis, since including or 
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excluding these measurements had virtually no effect on the mixed models. Readers 
who wish to examine the difference in modeling results may consult table S1 and the 
corresponding matlab scripts.  
 
Plasma metabolite concentrations 
Plasma TG was measured using a commercially available kit (Roche diagnostics). 
Plasma insulin was measured by ELISA (Alpco). Glucose was measured on whole 
blood using an Accu-Check® glucose meter. Plasma TC and free cholesterol was 
measured by colorimetric assay according to the CHOD-PAP method [17]. HDL-c was 
measured by measuring total cholesterol in the supernatant after precipitating apoB-
containing lipoproteins with polyethylene glycol 6000 (PEG6000) [18]. 
 
Hepatic metabolite concentrations 
Liver lipids were extracted using a Bligh & Dyer procedure [19]. Liver lipids were 
then redissolved in 2% Triton-X100 and measured using a commercially available kit 
for measurement of triglyceride (Roche) and the CHOD-PAP method for TC and free 
cholesterol measurement [17]. Phospholipids after Bligh & Dyer extraction were 
measured according to Bottcher et al. [20]. 
 
RNAseq analysis 
RNA was isolated using a commercially available kit (RNeasy, Qiagen). Initial quality 
check of and RNA quantification of the samples was performed by capillary 
electrophoresis using the LabChip GX (Perkin Elmer). Non-degraded RNA-samples 
were used for subsequent sequencing analysis. Sequence libraries were generated using 
the 3’QuantSeq sample preparation kits (Lexogen). The obtained cDNA fragment 
libraries were sequenced on an Illumina HiSeq2500 using default parameters (single 
read 1x50bp) in pools of multiple samples. The obtained fastQ files where aligned to 
build Mus_musculus.GRCm38 ensembleRelease 82 reference genome using 
hisat/0.1.5-beta-goolf-1.7.20 [21] with default settings. Before gene quantification 
SAMtools/1.2-goolf-1.7.20 was used to sort the aligned reads [22]. The gene level 
quantification was performed by HTSeq-count HTSeq/0.6.1p1 using –mode=union 
[23]. Analysis of gene expression was performed in R [24]. Counts were normalized 
with the trimmed-mean of M-values normalization (TMM) method provided in the 
edgeR package [25]. Analysis of differential gene expression was done using voom 
transformation provided by the limma package [26]. A false disovery rate of 0.05 and a 
log2 fold change of 1 were taken as cut-off values for differentially expressed genes. 
To account for a batch effect introduced during RNA-isolation, this was included in the 
design of the linear model. For visualization of batch-controlled gene expression, batch 
effect was removed using the ComBat function of the R SVA-package [27]. Plots of 
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gene expression in this article were produced by making use of the R packages ggplot2 
[28] and superheat [29]. 
 
Liver histology 
Paraffin sections were stained with hematoxylin and eosin stain and Sirius Red. The 
slides where then scored for NASH according to Kleiner et al. [30]. The percentage of 
fibrosis was determined as follows: Three x4 digital images were obtained randomly 
from every section using the polarized light option. The 3 pictures covered 
approximately between 70-90% of specimen total surface area. The images were 
imported to ImageJ and subsequently analyzed using an in-house developed macro 
which was written to quantify the area, percentage and integrated density of positively 
stained collagen fibers in every image using a camera specification with 226.7 ms 
exposure, sensitivity set to ISO 200 and snapshot resolution of 2560 x 1920.  
 
VLDL-TG production 
Animals were injected intraperitoneally with poloxamer 407, an inhibitor of lipoprotein 
lipase, at a dose of 1000 mg/kg BW [31]. After 30, 60 and 180 minutes a small volume 
of blood was collected for measurement of triglycerides. VLDL-TG production was 
then calculated by multiplying the slope of increased TG concentration by the 
theoretical plasma volume based on their body weight, where a blood volume of 75 
ml/kg is assumed with a hematocrit of 0.45.  
 
Hepatic de novo lipogenesis 
Animals were provided with drinking water containing 2% C13-acetate at 9 AM. Food 
was removed the following day at 9 AM and animals sacrificed at 1 PM. Liver lipids 
were isolated using the Bligh & Dyer procedure. Isolated lipids were derivatized in 
acidic methanol at 90 °C for 4 h. Mass-isotopomer distribution of methylated fatty 
acids was then measured by LC-MS. Hepatic de novo lipogenesis and elongation was 
calculated as described previously [32–34]. 
 
Endogenous glucose production 
Endogenous glucose production was determined as described previously with minor 
modifications[35]: Food was removed at 9 AM and the experiment started at 1 PM. At 
1 PM, animals received 0.1 mg/g [6,6]-D2-glucose intraperitoneally in a concentration 
of 30 mg/ml. Immediately before, and 10, 20, 30, 40, 50, 60, 75 and 90 minutes after 
the intraperitoneal injection, a small amount of blood was collected on filter paper and 
glucose measured with an Accu-Check® glucose meter. Glucose was then extracted 
from the dried blood with a water/ethanol mixture. After the solution was evaporated 
under nitrogen flow at 60 °C, the residue was derivatized to glucose penta-acetate by 
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adding 100 µl pyridine and 200 µl acetic anhydride to the extracted glucose and 
heating at 60 °C for 30 minutes. After evaporation under nitrogen flow, the residue was 
then dissolved in 200 µl ethyl acetate for analysis by GC-MS. GC-MS was performed 
with a Zebron ZB-1701 30m x 250 µm x 0,25 µm (Phenomenex) column under 
positive chemical ionization with ammonia ions monitored m/z 408-412 (m0-m4). After 
corrections for natural abundances according to Lee et al., the kinetics of the 
enrichment of glucose with D2-glucose were then used to estimate endogenous glucose 
production and related parameters according to van Dijk et al. [35]. 
 
Bile metabolite concentrations 
Gallbladder cannulation was performed under fentanyl – fluanisone anesthesia (1 
ml/kg). After allowing the gallbladder to empty for 5 min, bile was collected for 20 
min while mice were placed in an incubator to maintain body temperature. Bile 
production was measured by weighing the collected bile. Quantification of biliary bile 
acids was performed as follows. Bile samples were 1000x diluted with MilliQ. After 
homogenizing, 25 µL diluted bile was aliquoted into a clean tube for bile acid analysis. 
For every 10 samples prepared, one quality control standard plasma was included. To 
each sample 250 µL internal standard solution was added and vortexed for 1 min. D4-
cholic acid, D4-chenodeoxycholic acid, D4-glycochenodeoxycholic acid, D4-
glycocholic acid, D4-taurochenodeoxy-cholic acid and D4-taurocholic acid were used 
as internal standards. Samples were then centrifuged at 15,800 x g and the supernatant 
transferred to a clean glass tube. The fluid was evaporated under nitrogen at 40 °C. If 
samples were not measured immediately, they were stored in at -20 °C until further 
analysis. Samples were then reconstituted in 200 µL 50% methanol in water, vortexed 
for 1 minute and centrifuged for 3 min at 1,800 x g. The supernatant was transferred 
into a 0,2 µm spin-filter and centrifuged at 2,000 x g for 10 min. After filtering, the 
samples were transferred into LC-MS vials and analyzed (10 µL injection volume). For 
separation a Nexera X2 Ultra High Performance Liquid Chromatography system 
(SHIMADZU, Kyoto, Japan), coupled to a SCIEX QTRAP 4500 MD triple quadrupole 
mass spectrometer (SCIEX, Framingham, MA, USA) (UHPLC-MS/MS) was used, 
with an ACQUITY UPLC BEH C18 Column (1.7 µm x 2.1 x 100 mm) equipped with 
a ACQUITY UPLC BEH C18 VanGuard Pre-Column (1.7 µm x 2.1 x 5 mm), (Waters, 
Milford, MA, USA). Separation was achieved in 28 min using 10 mM ammonium 
acetate in 20% acetonitrile (mobile phase A) and 10 mM ammonium acetate in 80% 
acetonitrile (mobile phase B), total flow rate: 0.4 ml/min. To quantify biliary lipids, 
lipids were isolated from 15 µl of bile using Bligh & Dyer extraction [19] and split in 
10 µl for cholesterol measurement via homemade assay according to Gamble and 5 µl 




Feces metabolite concentrations 
Neutral sterols and bile acids were measured by GC-MS as described previously [37], 
with a minor modification, where fecal neutral sterols are extracted from 50 mg of 
feces with 2 x 2 ml petroleum ether after saponification in 1 ml of alkaline methanol, 
instead of 3 x 3 ml. 
 
Statistical analysis 
While we aimed for a fully longitudinal study, some parameters are currently not 
accessible for multiple measurements in the same animal, since they require 
terminating the animal. Such cross-sectional data between different time points were 
compared with one-way ANOVA, or when a non-parametric test was indicated, by a 
Kruskal-Wallis test and the p-value adjusted for multiple comparisons by Tukey-
Kramer correction. For all truly longitudinal data, mixed-linear effects models were 
used to establish whether data was best described as biphasic or as either linearly 
increasing or decreasing, using the MATLAB and Statistics Toolbox Release 2015b 
software. Values vs. fitted-value plots were used to check for the presence of 
heteroscedasticity and non-normal distribution of the residuals. When the model was 
best described as biphasic, best linear unbiased estimates were used to calculate the 
peak of the fitted model. To calculate marginal and conditional R2, we made use of the 
formulas described by Johnson (2014) [38]. 
 
marginal R2 =  var_fixed / (var_fixed + var_random + var_resid) 
 
conditional R2  = (var_fixed + var_random) / (var_fixed + var_random + var_resid) 
 
In the setting of a mixed-effect model, the marginal R2 reflects the variation explained 
by the fixed-effects of the linear model. In our case, by using time as only variable, it 
reflects how much of the variation is explained by the coefficients that fit the group 
mean response through time. The conditional R2, in contrast, reflects how much of the 
variation in time is explained when including the individual response to the diet. That 
is, when allowing coefficients for individual mice to be normally distributed around the 




Body weight and food intake 
Body weight rapidly increased in response to the HFCD and then plateaued around 12 - 
16 weeks (Fig. 1). Mixed modeling suggests a maximum at 18 weeks, with a marginal 
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and conditional R2 of 0.47 and 0.98 respectively, illustrating the large variation in body 
weight between animals. Food intake was higher the first few weeks after introduction 
to the diet. Towards the end of the diet some animals showed increased food intake as 
well. We note that food intake is difficult to determine accurately, as the food pellets 
are crumbly and some animals are prone to spillage, especially immediately after 
introduction to the diet (Fig. S1). When applying a mixed model to the food intake, we 
find a better fit for a biphasic curve where the marginal response indicates a minimum 
at 13 weeks with a week-averaged daily food intake of 3.2 g and a daily food intake of 
3.7 and 3.8 g at the start and end of the experiment respectively. These results should 
be interpreted with caution since the marginal R2 is only 0.03. Median daily food 
intake was 3.1, 3.2, 3.3 and 3.2 gram for the 4, 9, 13 and 28 weeks cohorts 
respectively. We noted that individual median food intake correlated with maximum 
body weight attained for the 9, 13 and 28 weeks cohort (Fig. 2) but not for the 4 weeks 
cohort. The correlations of the 28 weeks cohort are only significant when drop outs are 
excluded. All in all, these results indicate that at least part of the variation in body 
weight observed may be explained by individual differences in food intake. 
 
Plasma lipid parameters 
Plasma triglyceride (Fig. 3A) and plasma total cholesterol (Fig. 3B) showed 
considerable changes and an interesting biphasic response to the HFCD. Inspection of 
the data in Fig. 3 suggests a maximum in plasma triglyceride and cholesterol between 
16 and 20 weeks after start of the diet. To test and quantify these observations, mixed 
linear effect models were used. Using time as the sole predictor variable, we found that 
for plasma triglyceride and total cholesterol model specifications with third power and 
quadratic fixed effects respectively achieved a better fit to the data than the 
corresponding mixed effect models with time as a linear predictor. This supports that 
the observed response in plasma triglyceride and total cholesterol is indeed biphasic. 
Plasma TG was transformed by taking the square root to mitigate heteroscedasticity in 
the residuals. We found a marginal and conditional R2 of 0.19 and 0.9 for plasma 
triglyceride and 0.50 and 0.87 for plasma total cholesterol, underlining that the random 
effects (i.e. individual contribution) explain a large proportion of the variance. The 
terms of the fixed effects point to a maximum at 18 weeks for both plasma triglyceride 
and total cholesterol. Inspection of the HDL-c data does not convey a clear trend 
through time (Fig. 3C). However, similar to plasma TG, mixed modeling results in the 
best data fit for third power model, leading to a marginal and conditional R2 of 0.14 
and 0.57 respectively and a maximum at 9 weeks. Consistent with the findings for 
plasma TC, mixed modeling of non-HDL-c shows a maximum at 20 weeks, with a 




Plasma glucose and insulin 
In line with effects on TG and cholesterol levels, plasma glucose and insulin also 
reveal a biphasic response (Fig. 4), yet the response peaked much earlier and was 
apparently not directly coupled to changes in lipids. Mixed modeling shows that for 
both glucose and insulin a third power mixed effect model fits the data best, with a 
peak for glucose at 6 weeks and a peak for insulin at 10 weeks. Marginal and 
conditional R2 for plasma glucose and insulin were 0.18 and 0.28, and 0.28 and 0.8 
respectively.  
 
Liver lipid content 
Liver weight increased with the time spent on the HFCD (Fig. 5A). There appears a 
trend for liver TG to first increase and then decrease. However, even the most marked 
difference in liver TG between 13 weeks and 28 weeks does not reach statistical 
significance (p = 0.053) (Fig. 5B). Similarly, liver total cholesterol follows the trend of 
liver triglycerides (Fig. 5C). One-way ANOVA shows no significant differences. Liver 
free cholesterol remains constant through time, with a trend for an increased free 
cholesterol concentration at the latest time point (Fig. 5D). One-way ANOVA shows 
that the difference between 28 weeks and both 4 (p=0.01) and 9 weeks (p=0.02) were 
statistically significant. In contrast, liver phospholipids show a trend for being 
decreased at the last time point when compared to the first time point (fig. 5E). One-
way ANOVA shows that liver phospholipid concentrations after 4 weeks HFCD 
differed significantly from 9 weeks (p=0.01), 13 weeks (p=0.04) and 28 weeks 
(p=0.02).  
 
Liver NASH scores 
Liver NASH scores and fibrotic area increased with time spent on HFCD (Fig. 5F-G). 
NASH scores show a statistically significant difference both between 4 weeks and 13 
(p=0.047) and 28 weeks (p<0.01) and between 9 weeks and 28 weeks (p<0.01), using 
the one-way kruskal-wallis test. Fibrotic area was remarkably similar for the first 3 
months while fibrotic area after 28 weeks HFCD was notably increased (p<<0.01). 
 
RNAseq analysis 
To investigate the effect of 6 months HFCD feeding on gene expression in the 
metabolic networks of the mice, we determined global mRNA levels in the livers using 
the Lexogen platform. The number of differentially expressed genes after 9 weeks, 13 
weeks and 28 weeks HFCD diet (compared to 4 weeks HFCD) was surprisingly low; 1, 
63 and 159 respectively, against 6843 genes with sufficient sequencing depth. Of 
differentially expressed genes, many were associated with inflammation and fibrosis 
and increased in expression over time. For example, the collagen subunits Col1a1, 
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Col1a2, Col3a1, Col6a3 and the chemokines Ccl6, Cxcr4 were all increased in 
expression at 13 weeks and 28 weeks HFCD. Furthermore, we note high expression of 
glutathion transferases (Gstm1, Gstm3) and galectins (Lgals1, Lgals3) at 13 and 28 
weeks of HFCD. When focusing on differentially expressed genes with roles in 
metabolism we note the following. G6pc expression was increased (logFC=1.4, 
FDR=0.04) in the 9 weeks HFCD cohort, Lpl expression was increased in the 13 weeks 
cohort (logFC=1.4, FDR<0.001) and 28 weeks cohorts (logFC=1.9, FDR<1e-6), Pltp 
expression was increased in the week 13 cohort (logFC=1, FDR<0.001) and at 28 
weeks HFCD (logFC=1.1, FDR<1e-5), while Cyp7b1 (logFC=-1.5, FDR<1e-6), 
Cyp8b1 (logFC=-1.5, FDR<1e-6) and Slc10A1 (logFC=-1.3, FDR<1e-6) expression 
was decreased after 28 weeks HFCD. Though it may be expected that many genes 
important in the regulation of cholesterol homeostasis (Nr1h3, Nr1h2, Nr5a2, Srebf2, 
Insig, Scap, Hmgcr, Abcg5, Abcg8) and of triglyceride synthesis (Srebf1, Fasn, Dgat2, 
Acly, Acaca, Acacb, Scd1, Gpd1) would be differentially expressed over time, this was 
actually not the case. A heat map is provided with the genes mentioned above (Fig. 6), 
a full list of differentially expressed genes over time may be found in a supplemental 
file (Suppl. File RNA_analysis). 
 
VLDL-TG production and hepatic de novo lipogenesis 
In spite of both liver lipid content and histology showing large changes over time, we 
found no differences in VLDL-TG production. VLDL-TG production was 162 (46), 
176 (29), 151 (44) and 136 (54) µmol TG/kg/hour for 4, 9, 13 and 28 weeks 
respectively (SDs are given within brackets), thus showing no clear trend over time 
(Fig. 7). Fractional de novo lipogenesis (i.e. the percentage of newly synthesized fatty 
acids) appears higher at 13 and 28 weeks, with significant differences between 4 and 9 
weeks on the one hand and 13 and 28 weeks on the other hand for de novo production 
of palmitate (C16:0, Fig. 8A) and stearate (C18:0, Fig. 8B). Oleate (C18:1, Fig. 8C) 
fractional de novo lipogenesis was also signficantly different between 9 weeks 
compared to 13 and 28 weeks. Fractional de novo lipogenesis attributable to chain 
elongation of palmitate (Fig. 8D-E) shows a mixed picture, with stearate contribution 
of chain elongation being different only between 9 weeks and the 4, 13 and 28-week 
time points, whereas the oleate contribution to chain elongation showed significant 
differences between 4 and 28 weeks.  
 
Endogenous glucose production 
Tracer kinetics showed a trend for decreasing AUC and mean residence time over time 
whereas for bioavailability, apparent volume of distribution, metabolic clearance rate 
and glucose pool size the parameters decreased from 3 to 15 weeks HFCD followed by 
an increase at the 27 weeks time point (Fig. S3). Similarly, and in line with the 
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decreasing trend for plasma glucose and the behaviour of the metabolic clearance rate 
with time spent on the HFCD (Fig. 9A), it was seen that endogenous glucose 
production decreased over time during the first three months, followed by an increase 
towards 27 weeks of HFCD (Fig. 9B). We observed no trend for overall insulin 
sensitivity (Fig. 9D).  However, peripheral insulin sensitivity showed a decrease with a 
minimum around 9 weeks followed by an increase towards 27 weeks. In contrast, the 
hepatic insulin sensitivity showed a very mixed picture, with values diverging the most 
at 9 weeks HFCD and then converging slightly at 27 weeks HFCD. Mixed modeling 
suggests a minimum of endogenous glucose production at 17 weeks of HFCD. 
Marginal and conditional R2 were 0.53 and 0.53 respectively. Peripheral insulin 
sensitivity showed a minimum at 15 weeks and marginal and conditional R2 of 0.16 
and 0.47 respectively. 
 
Biliary bile acid and cholesterol secretion 
In line with the biphasic curve observed for plasma and liver lipids, biliary bile acid 
production, cholesterol production, and phospholipid production also show a biphasic 
trend (Fig. 10). One-way ANOVA shows that differences over time for bile acid 
production do not reach statistical significance. Biliary cholesterol production is 
different between 9 and 13 weeks (p<0.001), and 28 weeks (p=0.03). Biliary 
phospholipid production is also different between 9 and 13 (p=0.002) on one hand and 
between 13 and 28 weeks (p = 0.04) on the other hand. 
 
Fecal neutral sterol and bile acid excretion 
Fecal neutral sterol excretion appears to increase with time. In contrast, fecal bile acid 
excretion does not show an obvious trend over time (Fig. 11). Mixed linear modeling 
indicates however that in both cases a quadratic model is appropriate. We then arrive at 
a minimum of fecal neutral sterol excretion at minus 4 weeks, indicating that the group 
mean response only increases in the experimental time-frame, and a minimum of bile 
acid production at 9 weeks. Marginal and conditional R2 for fecal cholesterol excretion 
was found to be 0.18 and 0.75 respectively, whereas marginal and conditional R2 for 
fecal bile acid production was 0.02 and 0.69 respectively. Clearly, there is a large 




ApoE*3L.CETP-mice fed an HFCD show a biphasic course for plasma TG, TC, HDL-
c, glucose, insulin, endogenous glucose production and peripheral insulin sensitivity, 
which at least for the changes in plasma lipids, is reminiscent of similar observations in 
cross-sectional studies in man. At the same time we must note that the response of 
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animals to the HFCD is extremely heterogenic for which the reasons are not known. 
We further found no change in VLDL-TG production between the different time 
points. This indicates that differences in plasma lipids over time are likely the result of 
changes in clearance. Another interesting observation was that plasma insulin peaked 
before plasma TG peaked, which suggests that these two hallmarks of metabolic 
syndrome are not similarly linked to body weight gain over time. 
 
Inter-individual variation in response to HFCD is large in E3L.CETP mice 
A large degree of inter-individual variation was observed in this study. The mouse 
strain used here, E3L.CETP and the related apoE*3-Leiden strain, are known for their 
heterogeneity in response to Western-type diets. In fact, animals that do not respond to 
a diet containing 16% fat and 0.1-0.25% cholesterol with respect to a sufficient raise in 
TC are usually excluded from subsequent studies on atherosclerosis development. 
While we can not currently explain the hetereogeneity, the observation that median 
food intake correlated with the maximum attained body weight, suggests that part of 
the observed heterogeneity may be attributed to individual differences in food intake. 
Furthermore, it should be noted that phenotypic heterogeneity is also observed in its 
background strain C57BL/6J, and therefore not solely attributable to the transgenes in 
E3L.CETP. C57BL/6J non-uniform response to high-fat diets have been brought to the 
attention before, and has prompted researchers to stratify individuals for subsequent 
study [39,40]. In fact, homozygosity in inbred mice has long been known to increase 
variability [41].  
 
Biphasic response in plasma insulin and peripheral insulin sensitivity 
We found that plasma insulin increases on HFCD and peaks early, while notably 
peripheral insulin sensitivity, as derived from stable-isotope tracer studies, increased 
over time after an initial decrease. The majority of studies in mice find increased 
insulin resistance with age on high-fat diet [42]. However, decreasing insulin resistance 
with age beyond 24 weeks of high-fat diet has also been observed in C57BL/6J-mice 
[43]. Cross-sectional studies in humans show that insulin resistance increases with age 
[3,4,44]. In our study overall insulin sensitivity did not change while peripheral insulin 
sensitivity increased in the second phase, indicating that E3L.CETP mice on HFCD do 
not behave similar to humans with regard to changes in insulin resistance beyond 
approximately 4 months of HFCD. It is unclear what caused the increased peripheral 
insulin sensitivity in this study and whether this finding is specific for this mouse strain 
or a more general phenomenon of mice subjected to HFCD for longer periods of time. 
Assuming the latter, a potential mechanism may be that over the course of the HFCD, 
cholesterol and oxysterol metabolites accumulate in adipose tissue and lead to 
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increased activation of NR1H3 (a.k.a. LXR), in turn leading to increased peripheral 
insulin sensitivity [45].  
 
Biphasic response in dyslipidemia reminiscent of decrease in plasma TG in mouse 
models of accelerated ageing 
We observed a biphasic response in dyslipidemia to HFCD with plasma TG and TC. 
Data regarding the development of dyslipidemia in E3L.CETP mice on HFCD over an 
extended time period have not previously been reported. However, a longitudinal study 
in apoE3*Leiden mice on a high-fat diet without added cholesterol up to 3 months 
showed a gradual increase in plasma TG and plasma TC, which is in agreement with 
the current study [42]. Interestingly, plasma TG in the Ercc1-/Δ mouse model of 
accelerated aging at 21 weeks of age is similar to wild-type mice aged 26-34 months, 
and decreased compared to 7 weeks old wild-type mice [46]. In other words, a decrease 
in plasma TG in mice is associated with ageing, and the observed changes in 
lipoprotein metabolism of E3L.CETP mice on HFCD may share some mechanisms 
with those active in the ageing process.  
 
VLDL-TG production does not explain biphasic pattern of dyslipidemia 
In this study, VLDL-TG production was not significantly different between measured 
time points, suggesting that the differences observed in dyslipidemia are likely due to 
differences in the clearance of apoB-lipoproteins. In contrast, earlier studies in 
apoE3*Leiden mice on a HFCD showed increased VLDL-TG production leading to a 
peak at 45 days compared to 100 days of age [47]. In our experiment however, animals 
were aged >100 days at the start of the experiment. Together these findings suggest 
that VLDL-TG production in apoE3*Leiden and E3L.CETP mice are increased at a 
younger age on a HFCD, however may decrease and stabilize to a steady value once 
animals reach maturity. Given that VLDL-TG production was not changed over time, 
the observed changes in plasma TG are likely to be the result of changes in triglyceride 
hydrolysis activity. VLDL-TG production as primary cause for variation in plasma TG 
can however not be completely excluded, given the heterogeneity observed between 
animals and that with the currently available methods, VLDL-TG production in an 
animal can be measured only once. The fact that we observed no correlation between 
basal plasma TG and VLDL-TG production rate (Fig S4) argues against this possibility 
however. 
 
Contribution of VLDL-production and clearance to dyslipidemia in humans 
Since E3L.CETP mice have a ‘humanized’ lipoprotein metabolism, it is of interest to 
compare findings in lipid parameters of this study to those found in humans. Whereas 
in the current study differences in dyslipidemia appear to be mediated by differences in 
149 
 
lipoprotein clearance, dyslipidemia observed in metabolic syndrome in men is 
considered to be caused by an increase in VLDL-production [48]. Furthermore, 
increased age is associated with increased VLDL-production as well as reduced LDL-
clearance in men [49]. On the other hand, studies in women and mixed groups suggest 
that age-related increases in triglycerides and cholesterol are due to decreased 
catabolism of lipoproteins [50,51]. All in all, we must conclude that in humans both 
VLDL-TG production and clearance can contribute to differences in plasma TG. 
Although a limitation of this study was that triglyceride hydrolysis activity as such was 
not evaluated, the lack of significant differences in VLDL-TG production over time 
suggests that changes in triglyceride hydrolysis activity was the predominant factor in 
the dyslipidemia observed here. 
 
Gene expression profiles do not follow the response to HFCD in metabolic fluxes 
Gene expression analysis of E3L.CETP – mice on HFCD for 4, 9, 13 and 28 weeks 
showed an increase in expression of genes involved in inflammation and fibrosis. 
Furthermore, we observed that metabolic differentially expressed genes encoding 
metabolic enzymes showed little correlation with the measured metabolic fluxes. First, 
the increased G6pc expression after 2 months HFCD does not coincide with increased 
endogenous glucose production. It should be noted that G6pc expression is mostly 
linked to increased glucose production in primary hepatocytes, whereas in vivo studies 
show that changes in G6pc expression do not necessarily result in changes in 
endogenous glucose production [52,53]. Secondly, a decrease of Cyp7b1, Cyp8b1 and 
Slc10a1 in expression over time, does not coincide with a concomitant decrease in 
biliary bile acid secretion. This is in agreement with earlier findings where changes in 
bile acid gene expression may affect composition of bile acids but has little bearing on 
the total biliary bile acid secretion [54,55]. Finally, absence of Pltp has previously been 
shown to impair VLDL-TG production in mice [56]. Here, we observed that Pltp was 
decreased in expression over time, with however no changes in VLDL-TG production. 
Overall, the findings in the present study may serve as another reminder that gene 
expression can generally be considered as a poor predictor of metabolic fluxes [57–59].  
 
Linear relation between body weight and liver weight 
While the liver weight increased over time, hardly any significant changes through 
time on HFCD for the liver lipids were observed. Free cholesterol however increased 
with time, which is in line with other studies, in which free cholesterol accumulates in 
the liver on high-fat high-cholesterol diet and contributes to NASH development [60]. 
Interestingly, we further observed a near linear relation between body weight and liver 
weight, suggesting a redistribution of fat from adipose tissue to liver. In contrast, the 




Modest increase in hepatic de novo lipogenesis over time 
Changes in hepatic de novo lipogenesis were more evident, being increased at 13 and 
28 weeks HFCD compared to 4 and 9 weeks time points. This is in line with other 
mouse studies where high fat diet stimulated hepatic de novo lipogenesis and this 
effect was stronger with longer time spent on high-fat diet [61]. In human studies, the 
relation between age and hepatic de novo lipogenesis has received little attention to 
date, with one study reporting increased hepatic de novo lipogenesis in elderly 
compared to younger controls [62]. More studies are necessary to estabilish these 
relations. 
 
Biliary bile acid and cholesterol fluxes 
We observed no clear pattern in biliary bile acid secretion over time. Dietary 
cholesterol increases bile acid production in mice within 3 weeks [63]. On the other 
hand, ageing has been reported to decrease bile acid production in both humans and 
mice [64,65]. In contrast, biliary cholesterol production increases with age in man [65]. 
While we observed an increase in biliary cholesterol production between 28 weeks and 
9 weeks, the difference between 28 weeks and 4 weeks HFCD was not statistically 
significant. All in all, there appears to be no ageing effect in bile production in 
E3L.CETP – mice on HFCD within 28 weeks.  
 
Role of cholesterol absorption in dyslipidemia in mice and humans 
Dyslipidemia in mice is generally elicited through feeding HFCD, since high-fat diet 
without added cholesterol is not sufficient [66]. It follows that cholesterol absorption 
may be an important factor in the response to the HFCD. Here, we found that fecal 
neutral sterol excretion increased with time on HFCD, indicating that dietary 
cholesterol absorption of E3L.CETP mice on HFCD decreases as mice age. Of note, 
C57BL/6J-mice on a standard diet show the opposite, i.e. an increase in cholesterol 
absorption with increasing age [67]. In humans, cholesterol absorption is an important 
predictor for dyslipidemia [68,69]. Moreover, a cross-sectional study in Finland found 
that healthy 75-year old men show decreased cholesterol absorption compared to 50 
year-old men [70]. Taken together, it appears that E3L.CETP mice on a HFCD follow 
a similar trajectory in cholesterol absorption as humans. While at this point it is not 
clear whether these observations are caused by comparable mechanisms, it is intriguing 







Insulin resistance precedes dyslipidemia 
We observed in this study that insulin resistance preceded dyslipidemia. Similar 
observations have been made in other animal as well as human studies. Barnard et al. 
observed that first fasting insulin levels increased, i.e. within 2 weeks, and then plasma 
TG increased in unison with glycerol release and fat cell size in female Fischer rats on 
high-fat high-sucrose diet [71]. Similarly, in the San Antonio Heart Study, fasting 
plasma insulin was shown to be predictive for increased plasma TG at 8-years follow 
up in humans [72,73]. Assuming that a common cause for insulin resistance and 
dyslipidemia exists, these findings imply that insulin resistance is triggered first and 
dyslipidemia only occurs beyond a threshold. The idea of a threshold is consistent with 
the paradigm of insulin resistance being caused by free fatty acids leaking into the 
system once the capacity of white adipose tissue to store fat is exceeded. Recently, Van 
Beek et al. found that in C57Bl/6J mice, plasma TG increases sharply once mice 
exceed  a body weight around 40 gram [74]. While here a similar pattern is observed 
(Fig. S5), the variation is higher, suggesting the presence of another factor that 
modulates plasma TG. Similarly, while Van Beek et al. find a close relationship 
between body weight and plasma insulin [74], here we find that this relationship is less 
distinct, and that body weight in the first three months of HFCD is associated with 
higher plasma insulin levels than in the second three months of HFCD (Fig. S5). This 
change in relation between body weight and both insulin resistance and dyslipidemia 
implies that, if fatty acids are considered the culprit, a fatty acid sink must develop 
over time, mitigating both dyslipidemia and insulin resistance. 
 
In conclusion 
Overall, E3L.CETP mice on a HFCD show a biphasic response in metabolic 
parameters through time, and may prove to be an adequate model to study age-
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Body weights of male E3L.CETP-mice on HFCD over time. Note that body weight plateaus around 12-15 
weeks. Blue-dotted lines represents the group mean response of the mixed model. Red lines connect 
measurements performed on the same individual animal. Mixed modeling suggests a maximum at 18 
weeks HFCD. 
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Correlations between individual median food intake over time with the maximally attained body weight of 
the respective cohorts. Red points indicate animals that dropped out before the end of the experimental 
period. Pearson correlations shown are with dropouts excluded. When including dropouts correlations are 








Plasma triglyceride (A), total cholesterol (B), HDL-C (C) and non-HDLC (D), for male apoE*3L.CETP 
mice as measured at the indicated time points. Data for the respective cohorts was pooled when measured 
on the same time point.  Blue-dotted lines represents the group mean response of the mixed model. Red 










Whole blood glucose (A) and plasma insulin (B) of male apoE*3L.CETP mice as measured at the 
indicated time points. Data for the respective cohorts was pooled when measured on the same time point.  
Blue-dotted lines represents the group mean response of the mixed model. Red lines connect 
measurements performed on the same individual animal. Note the biphasic response and that glucose 

























Liver weights (A), liver triglyceride (B), total cholesterol (C), free cholesterol (D) and phospholipid (E) 
concentrations, and NASH scores (F) and fibrotic area (G) of livers in male apoE*3L.CETP cohorts 
sacrificed after 4, 9, 13 and 28 weeks HFCD respectively. NASH scores show a statistically significant 
difference both between 4 weeks and 13 (p=0.047) and 28 weeks (p<0.01) and between 9 weeks and 28 
weeks (p<0.01), using the one-way kruskal-wallis test. Fibrotic area was remarkably similar for the 
cohorts sacrificed up to 13 weeks while fibrotic area after 28 weeks HFCD diet was notably increased 
(p<0.01). N = 10, 10, 9 and 21 for 4, 9, 13 and 28 weeks HFCD diet respectively. Significant differences 












VLDL-TG production in the respective cohorts does not convey a clear up or downward trend. One-way 
ANOVA shows no significant differences between the time points. N = 10, 9, 9 and 16 for 4, 9, 13 and 28 
weeks HFCD diet respectively. 
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Fractional de novo lipogenesis for palmitate (C16:0) (A) , stearate (C18:0)  (B) , oleate (C18:1) (C),  and 
chain elongation of palmitate to stearate (C18:0) (E) and to oleate  (C18:1) (F), across the respective 
cohorts. N = 10, 9, 10 and 17 for 4, 9, 13 and 28 weeks HFCD diet respectively. Significant differences, 























Steady state glucose (A), post-test plasma insulin (B), endogenous glucose production rate (C) of male 
E3L.CETP mice on HFCD. From these values we can calculate insulin sensitivity (D), peripheral insulin 
sensitivity (E) and hepatic insulin sensitivity (F). Note that peripheral insulin resistance decreases and 
increases over time while hepatic insulin resistance does not. Blue-dotted lines represents the group mean 
response of the mixed model. Red lines connect measurements performed on the same individual animal. 









Biliary bile acids (A), biliary neutral sterol (B) and biliary phospholipid secretion rate (C) in male 









Fecal neutral sterol (NS) and bile acid excretion in male E3L.CETP – mice on HFCD diet at 3 weeks (n = 
30), 6 weeks (n=16), 9 weeks (n=30), 10 weeks (n=16), 13 weeks (n=30), 16 weeks (n=15), 17 weeks 
(n=29), 21 weeks (n=29), 22 weeks (n=14),  27 weeks (n = 24) and 28 weeks (n =14). The blue-dotted line 
represents the group mean response of the mixed model. Red lines connect measurements performed on 
the same individual animal. 
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